Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 289

1. Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis Frontiers in Pharmacology · 2023 · 13 citations
2. Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer Frontiers in Oncology · 2021 · 1 citations
3. Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response International Journal of Endocrinology · 2026
4. Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq” Journal of cancer research updates · 2026
5. Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study. Journal of Clinical Oncology · 2024
6. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study Cancer Communications · 2021 · 147 citations
7. Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study Drug Design Development and Therapy · 2025
8. Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings Journal of patient-reported outcomes · 2019 · 12 citations
9. Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial The Oncologist · 2024 · 9 citations
10. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm Asia-Pacific Journal of Clinical Oncology · 2018 · 4 citations

Community

— no results